- Location
- 155 College Street | Room 208 | Toronto, ON M5T 1P8
- Series/Type
- DLSPH Event
- Dates
- July 17, 2019 from 12:00pm to 2:00pm
Links
Anti-microbial resistance undermines effective infection control and treatments. Can emerging technologies in vaccinology curb this threat?
About this Event
Description
Microbes (such as bacteria, parasites, and fungi) resistant to modern drug therapies undermine effective infection control in Canada and globally. Although anti-microbial drugs remain effective solutions, it is predicted by 2050, 10 million deaths world-wide could be attributable to anti-microbial resistance. Drug resistance can further complicate, or increase fatality, for patients who will undergo intensive surgery and people who are immune-comprised (e.g. cancer patients).
Can emerging technologies in vaccinology curb this threat?
The pipeline to develop new antibiotics has not been promising. However, evolving vaccine technologies make it possible for researchers to tackle more diseases. Chief Scientist and Head External R&D at GSK Vaccines Rino Rappuoli will present such technologies and how the development of new vaccines help curb the threat of drug resistance.
Agenda:
Registration, check-in: 11:50-12:05
Public Lecture (in person and web access tickets available): 12:10-1:00 pm
Reception 1:00-2:00pm
About the speaker:
Rino Rappuoli is Chief Scientist and Head External R&D at GSK Vaccines, based in Siena, Italy and Professor of Vaccines Research, Imperial College, London. Prior positions were: head of Vaccine R&D at Novartis, CSO of Chiron Corporation, and head for R&D at Sclavo. He earned his PhD in Biological Sciences at the University of Siena, Italy, and was visiting scientist at Rockefeller University and Harvard Medical School.